CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world.
Led by an experienced management team that has a strong track record of identifying, in-licensing and developing attractive clinical product candidates directed at validated targets with proven mechanisms of action (MoAs), CORXEL's diverse portfolio of clinical-stage product candidates has the potential to redefine treatment standards and address key limitations of current therapies for multiple cardiometabolic indications.
Company Details
- Employees
- 47
- Founded
- 2019
- Address
- 300 Connell Dr,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.corxelbio.com
- Keywords
- Biotech, Cardiometabolic, GLP-1, Stroke, Hypertension.
- HQ
- Berkeley Heights, New Jersey
Corxel Pharmaceuticals Questions
Corxel Pharmaceuticals's website is https://www.corxelbio.com
Corxel Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/corxel-pharmaceuticals
Corxel Pharmaceuticals has
47 employees.
View email and phone details for 47
employees at Corxel Pharmaceuticals.
Corxel Pharmaceuticals's industry is
Biotechnology Research
Corxel Pharmaceuticals's top competitors are
Imprint,
Evolveimmune Therapeutics,
Nilo Therapeutics,
Princeton Biopartners,
Protara Therapeutics,
Caladan Bio,
Jung+ Longevity,
Halda Therapeutics,
Anavex Life Sciences,
Synbio Technologies.
Corxel Pharmaceuticals's categories are Biotechnology Research
Corxel Pharmaceuticals's founding year is 2019
